81 related articles for article (PubMed ID: 5327216)
1. Corticosteroids and fluorouracil toxicity.
Horton J; Olson KB; Hosley HF
Arch Intern Med; 1966 Jun; 117(6):775-7. PubMed ID: 5327216
[No Abstract] [Full Text] [Related]
2. A clinical study of fluorouracil.
Nadler SH; Moore GE
Surg Gynecol Obstet; 1968 Dec; 127(6):1210-4. PubMed ID: 4882472
[No Abstract] [Full Text] [Related]
3. A clinical trial of oral 5-fluorouracil.
Khung CL; Hall TC; Piro AJ; Dederick MM
Clin Pharmacol Ther; 1966; 7(4):527-33. PubMed ID: 5939975
[No Abstract] [Full Text] [Related]
4. Experience with ftorafur treatment in breast cancer.
Karev NI; Blokhina NG; Vozny EK; Pershin MP
Neoplasma; 1972; 19(4):347-50. PubMed ID: 5054534
[No Abstract] [Full Text] [Related]
5. 5-fluorouracil intravenous infusion for 48 hours, repeated every two weeks.
Hill GJ; Grage TB; Wilson W; Ansfield FJ
J Surg Oncol; 1972; 4(1):60-70. PubMed ID: 5033956
[No Abstract] [Full Text] [Related]
6. Toxic effects of cis-dichlorodiammineplatinum(II) in man.
Von Hoff DD; Schilsky R; Reichert CM; Reddick RL; Rozencweig M; Young RC; Muggia FM
Cancer Treat Rep; 1979; 63(9-10):1527-31. PubMed ID: 387223
[TBL] [Abstract][Full Text] [Related]
7. [Results of 5-fluorouracil (5FU) treatment of malignant neoplasms].
Singer Z; Kuśnierczykówna J; Iwanicka B
Pol Tyg Lek; 1974 Jun; 29(24):1033-7. PubMed ID: 4845080
[No Abstract] [Full Text] [Related]
8. Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and CIS-platinum (II) diaminedichloride (NSC 119875).
Ellerby RA; Davis HL; Ansfield FJ; Ramirez G
Cancer; 1974 Oct; 34(4):1005-10. PubMed ID: 4607883
[No Abstract] [Full Text] [Related]
9. Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.
Innocenti F; Ratain MJ
Clin Cancer Res; 2002 May; 8(5):1314; author reply 1315-6. PubMed ID: 12006555
[No Abstract] [Full Text] [Related]
10. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
[TBL] [Abstract][Full Text] [Related]
11. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
[TBL] [Abstract][Full Text] [Related]
12. Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine.
van Groeningen CJ; Peters GJ; Leyva A; Laurensse E; Pinedo HM
J Natl Cancer Inst; 1989 Jan; 81(2):157-62. PubMed ID: 2909757
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of weekly maytansine given by iv bolus or 24-hour infusion.
Chahinian AP; Nogeire C; Ohnuma T; Greenberg ML; Sivak M; Jaffrey IS; Holland JF
Cancer Treat Rep; 1979; 63(11-12):1953-60. PubMed ID: 526928
[No Abstract] [Full Text] [Related]
14. Clinical studies with tubercidin administered by direct intravenous injection.
Bisel HF; Ansfield FJ; Mason JH; Wilson WL
Cancer Res; 1970 Jan; 30(1):76-8. PubMed ID: 4917978
[No Abstract] [Full Text] [Related]
15. Predicting fluorouracil toxicity: can we finally do it?
Ezzeldin HH; Diasio RB
J Clin Oncol; 2008 May; 26(13):2080-2. PubMed ID: 18299611
[No Abstract] [Full Text] [Related]
16. [Changes in the hematopoietic system during treatment with 5-fluorouracil].
Voznyĭ EK
Vopr Onkol; 1970 Apr; 16(4):64-7. PubMed ID: 5454548
[No Abstract] [Full Text] [Related]
17. [Clinical evaluation of procarbazine and fluorouracil in advanced lung cancer].
Bonadonna G; Monfardini S; Oldini C; Guzzon A; Di Pietro S
Tumori; 1969; 55(5):277-89. PubMed ID: 4909863
[No Abstract] [Full Text] [Related]
18. Unexpected increase in the bone marrow toxicity of mitomycin C (MMC).
Yoshimoto M; Saito M; Tada T; Kasumi KT
Br J Cancer; 2001 Mar; 84(5):736-7. PubMed ID: 11237399
[No Abstract] [Full Text] [Related]
19. A comparison of 5-fluorouracil administered by slow infusion and rapid injection.
Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
Cancer Res; 1972 Dec; 32(12):2717-9. PubMed ID: 4566290
[No Abstract] [Full Text] [Related]
20. Clinical and pharmacological studies of methotrexate-minimal leucovorin rescue plus fluorouracil.
Wiemann MC; Cummings FJ; Kaplan HG; Spremulli EN; Doolittle CH; Calabresi P
Cancer Res; 1982 Sep; 42(9):3896-900. PubMed ID: 6980707
[No Abstract] [Full Text] [Related]
[Next] [New Search]
